PRICE T ROWE ASSOCIATES INC /MD/ - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 168 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.73 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,632
-71.2%
2,407,347
-54.8%
0.00%
-75.0%
Q2 2023$26,498
-15.3%
5,331,400
-15.8%
0.00%
-20.0%
Q1 2023$31,273
-16.3%
6,330,304
+6.5%
0.01%
-16.7%
Q4 2022$37,374
-99.9%
5,941,797
+0.6%
0.01%
-40.0%
Q3 2022$63,800,000
+0.7%
5,907,316
+6.3%
0.01%
+25.0%
Q2 2022$63,375,000
+63.0%
5,559,176
+30.3%
0.01%
+100.0%
Q1 2022$38,870,000
-19.9%
4,266,735
+31.2%
0.00%0.0%
Q4 2021$48,513,000
-56.5%
3,251,528
-25.1%
0.00%
-63.6%
Q3 2021$111,512,000
+20.9%
4,338,991
+22.7%
0.01%
+22.2%
Q2 2021$92,198,000
-24.4%
3,535,184
+2.3%
0.01%
-25.0%
Q1 2021$122,023,000
+35.8%
3,456,753
-2.9%
0.01%
+33.3%
Q4 2020$89,849,000
-33.4%
3,559,793
-0.5%
0.01%
-43.8%
Q3 2020$134,914,000
-16.9%
3,577,684
-5.6%
0.02%
-20.0%
Q2 2020$162,321,000
+278.8%
3,790,786
+72.0%
0.02%
+185.7%
Q1 2020$42,856,000
-33.2%
2,204,534
-10.8%
0.01%
-12.5%
Q4 2019$64,184,000
-6.5%
2,470,510
-1.9%
0.01%
-20.0%
Q3 2019$68,646,000
+1.3%
2,518,672
-0.2%
0.01%0.0%
Q2 2019$67,740,000
-4.5%
2,522,906
+0.1%
0.01%0.0%
Q1 2019$70,949,000
+7.7%
2,519,508
+0.3%
0.01%
-9.1%
Q4 2018$65,888,0002,511,9980.01%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
VV Manager LLC 1,798,163$76,997,00067.53%
Wildcat Capital Management, LLC 1,515,524$64,895,00022.42%
TPG Group Holdings (SBS) Advisors, Inc. 19,716,306$844,252,00014.91%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 1,279,281$54,779,0007.69%
Coastal Bridge Advisors, LLC 463,117$19,831,0006.33%
DSAM Partners (London) Ltd 235,098$10,067,0002.63%
Casdin Capital, LLC 625,000$26,763,0001.58%
Alpine Global Management, LLC 150,000$6,423,0001.13%
Perceptive Advisors 1,543,790$66,105,0001.07%
Avoro Capital Advisors LLC 1,128,594$48,326,0000.96%
View complete list of ALLOGENE THERAPEUTICS INC shareholders